144822-63-9 Usage
General Description
The chemical "1-[5-O-[Bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-2-fluoro-beta-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione" is a complex compound with a fluorinated deoxyribonucleoside structure. It is composed of a pyrimidine base and a sugar molecule, and is commonly used as an antiviral and antitumor agent due to its ability to inhibit the replication of DNA and RNA. The compound's structure includes multiple phenyl groups, which contribute to its pharmacological activity. Due to its intricate and specific structure, this chemical has potential applications in the field of medicinal chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 144822-63-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,8,2 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 144822-63:
(8*1)+(7*4)+(6*4)+(5*8)+(4*2)+(3*2)+(2*6)+(1*3)=129
129 % 10 = 9
So 144822-63-9 is a valid CAS Registry Number.
InChI:InChI=1/C30H29FN2O7/c1-37-22-12-8-20(9-13-22)30(19-6-4-3-5-7-19,21-10-14-23(38-2)15-11-21)39-18-24-27(35)26(31)28(40-24)33-17-16-25(34)32-29(33)36/h3-17,24,26-28,35H,18H2,1-2H3,(H,32,34,36)/t24-,26+,27-,28?/m1/s1
144822-63-9Relevant articles and documents
Synthesis and anti-HIV activity of 2′-deoxy-2′-fluoro-4′-C-ethynyl nucleoside analogs
Wang, Qiang,Li, Yanfeng,Song, Chuanjun,Qian, Keduo,Chen, Chin-Ho,Lee, Kuo-Hsiung,Chang, Junbiao
supporting information; experimental part, p. 4053 - 4056 (2010/08/19)
Based on the favorable antiviral profiles of 4′-substituted nucleosides, novel 1-(2′-deoxy-2′-fluoro-4′-C-ethynyl-β-d-arabinofuranosyl)-uracil (1a), -thymine (1b), and -cytosine (2) analogs were synthesized. Compounds 1b and 2 exhibited potent anti-HIV-1 activity with IC50 values of 86 and 1.34 nM, respectively, without significant cytotoxicity. Compound 2 was 35-fold more potent than AZT against wild-type virus, and also retained nanomolar antiviral activity against resistant strains, NL4-3 (K101E) and RTMDR. Thus, 2 merits further development as a novel NRTI drug.